Articles from Regentis Biomaterials Ltd.

Herzliya, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the pricing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at an initial public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and estimated offering expenses payable by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 Ordinary Shares to cover over-allotments, if any.